General Comments / Chat, page-7504

Spot on @Kron00

The writing style within the Ann will be a bit dry but this will allow for the juicy stuff to be read by 1000s once peer reviewed and published in top notch scientific publications. This is where scientists and forward thinking clinicians read, chat, get excited and then it can be presented at conferences where BP will stand up and listen. @Vatzat then it will be revealed that Zan is CS1. No more hiding. How many read RAC Ann vs these journals? No need to answer.

I have no doubt DCB is moving rapidly toward a good outcome. I'm led to believe by my conversations that clinicians and scientists are already excited about Zans prospects. Damien has shifted the strategy. Whilst this may take some adjusting I think that we will have some great announcements in H2 and a clearer pathway going forward. He's in the States a lot and has reams of friends in the industry, including BP. He knows exactly what needs to happen to achieve the next steps. There is a step by step process to achieving the best outcome whether that be for patients or for shareholders. These need to work in tandem.

Sentiment will change here. I can't say when but I'm led to believe later in the year will be good and if interest rates slow or stop it'd be the perfect time. A few posters have said, when the buying starts it can fly to $6 very quick as the top 20 aren't going to sell. If the selling stops the buyers need to pay top dollar. Merchant will continue to play with us until that time imo.

Not financial advice. Just my lowly opinion